Year None202420232022202120202019 Mar 10, 2024 Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Mar 09, 2024 New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Re Mar 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 04, 2024 Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Op Mar 04, 2024 Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical R Feb 29, 2024 Arcutis to Present at the TD Cowen 44th Annual Health Care Conference Feb 28, 2024 Arcutis Announces Pricing of $150 Million Public Offering Feb 28, 2024 Arcutis Announces Proposed Public Offering Feb 28, 2024 Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Next page next › Last page last » Displaying 37 - 45 of 53
